NIH R01 · 2025
Engineering T Cell Adoptive Therapy for Glioblastoma
PROJECT SUMMARY This proposal centers on the use of T cell receptor (TCR) directed therapy in preclinical glioblastoma (GBM) models. GBM remains a difficult cancer to treat, and clinical outcomes remain poor. However, despite the seismic influence of immunotherapy in cancer, there remain no FDA approved immunotherapies for GBM. There are several reasons that underlie the difficulty in extending immune-based treatments to the central nervous system (CNS). GBM harbors few T cells and is considered “non-inflamed”, there is a paucity of dendritic cells in the brain parenchyma, and a myriad of immunosuppressive features has been identified in patients. The CNS is also immunologically specialized…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.